Your account is not claimed yet. You can sign up with ORCID to claim your account.

Lyndon Marc Evans (Marc Evans, M Evans)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 19

Top Venues

Diabetes, obesity & metabolism

Diabetic medicine : a journal of the British Diabetic Association

Diabetes therapy : research, treatment and education of diabetes and related disorders

International journal of obesity (2005)

This page only lists publications with an associated author ORCID identifier.

Publications

Lyndon Marc Evans, Joanna de Courcy, Elisabeth de Laguiche, Mads Faurby, Christiane Lundegaard Haas, Kasper Sommer Matthiessen, Adam Moore, Jonathan Pearson-Stuttard
Obesity-related complications, healthcare resource use and weight loss strategies in six European countries: the RESOURCE survey. International journal of obesity (2005) (2023)
Phil McEwan, Volker Foos, Becky Martin, Jieling Chen, Lyndon Marc Evans
Estimating the value of SGLT2 inhibitors within the context of contemporary guidelines and totality of evidence. Diabetes, obesity & metabolism (2023)
Jonathan Pearson-Stuttard, Tania Banerji, Silvia Capucci, Elisabeth de Laguiche, Mads D Faurby, Christiane Lundegaard Haas, Kasper Sommer Matthiessen, Aimee M Near, Jenny Tse, Xiaohui Zhao, Lyndon Marc Evans
Real-world costs of obesity-related complications over eight years: a US retrospective cohort study in 28,500 individuals. International journal of obesity (2005) (2023)
Lyndon Marc Evans, Abhishek Shankar Chandramouli, Mads Faurby, Kasper Sommer Matthiessen, Phillip Bredahl Mogensen, Subodh Verma
Healthcare costs and hospitalizations in US patients with type 2 diabetes and cardiovascular disease: A retrospective database study (OFFSET). Diabetes, obesity & metabolism 24 (7) (2022)
Lyndon Marc Evans, Sasha Berry, Avideh Nazeri, Samuel Joseph Paul Malkin, Donna Ashley, Barnaby Hunt, Stephen C Bain
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes. Diabetes, obesity & metabolism (2022)
Lyndon Marc Evans, Vamshi Ruthwik Anupindi, Mitch DeKoven, Elisabeth de Laguiche, Victoria Divino, Mads D Faurby, Christiane Lundegaard Haase, Kasper Sommer Matthiessen, Jonathan Pearson-Stuttard
Eight-year trends in obesity-related complications and health care cost progression in a US population with obesity: A retrospective cohort study. Diabetes, obesity & metabolism (2022)
Lyndon Marc Evans, Barrie Chubb, Samuel Joseph Paul Malkin, Sasha Berry, Jack Lawson, Barnaby Hunt
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11. Diabetes, obesity & metabolism (2022)
Lyndon Marc Evans, Susanne Engberg, Mads Faurby, João Diogo Da Rocha Fernandes, Pollyanna Hudson, William Polonsky
Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. Diabetes, obesity & metabolism (2021)
Lyndon Marc Evans, Linda Mellbin, Pierre Johansen, Jack Lawson, Abby Paine, Anna Sandberg
A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease. Endocrinology, diabetes & metabolism 4 (3) (2021)
Rebecca K Vincent, David M Williams, Lyndon Marc Evans
A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer? Diabetes, obesity & metabolism 22 (12) (2020)
Hayley Bennett, Amarjeet Tank, Lyndon Marc Evans, Klas Bergenheim, Phil McEwan
Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. Diabetes, obesity & metabolism 22 (7) (2020)
Stephen C Bain, A Bakhai, Lyndon Marc Evans, A Green, I Menown, William David Strain
Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. Diabetic medicine : a journal of the British Diabetic Association 36 (9) (2019)
Bryony E Langford, Lyndon Marc Evans, Tao Haskins-Coulter, Molly O'Connor, Harriet E O Cant, Lucy A Eddowes, Christopher Edmonds, Amarjeet Tank
Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes. Diabetes, obesity & metabolism 22 (1) (2019)
Stephen C Bain, A Bakhai, Lyndon Marc Evans, A Green, I Menown, William David Strain
An update to: Pharmacological treatment for type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. Diabet Med 2019; 36: 1063-1071. Diabetic medicine : a journal of the British Diabetic Association 37 (8) (2019)
Ian Pearce, Rafael Simò, Monica Lövestam-Adrian, David T Wong, Lyndon Marc Evans
Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. Diabetes, obesity & metabolism 21 (3) (2018)
P McEwan, H Bennett, K Bolin, Lyndon Marc Evans, K Bergenheim
Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA1c , weight and hypoglycaemic event incidence. Diabetic medicine : a journal of the British Diabetic Association 35 (5) (2018)
Lyndon Marc Evans, Roopa Mehta, Jens Gundgaard, Barrie Chubb
Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting. Diabetes therapy : research, treatment and education of diabetes and related disorders 9 (5) (2018)
Lyndon Marc Evans, Plamen Kozlovski, Päivi M Paldánius, James E Foley, Vaishali Bhosekar, Carmen Serban, Angelo Avogaro
Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. Diabetes therapy : research, treatment and education of diabetes and related disorders 9 (1) (2017)
Lyndon Marc Evans, Sayeed Achha, Cheryl Neslusan
Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK. Diabetes therapy : research, treatment and education of diabetes and related disorders 8 (5) (2017)

Lyndon Marc Evans.css-eqlu8i{font-size:small;padding-left:4px;} (Marc Evans, M Evans)

Publication Activity (10 Years)

Top Topics

Top Venues

Lyndon Marc Evans (Marc Evans, M Evans)